Strategic Innovation Drives Growth in Latin America

Q: How is Eurofarma expanding its presence in the Mexican market?

A: Eurofarma is a true multinational enterprise. Operating across 24 countries in Latin America the United States, and Africa, Eurofarma has established a dominant regional presence as a leading Brazilian-headquartered pharmaceutical group. We entered the Mexican market over six years ago to build a footprint in one of Latin America's most critical and high-potential healthcare sectors.

Our Mexican subsidiary has experienced accelerated growth over the past five years. Although we do not operate a direct local manufacturing plant in Mexico, relying instead on regional production facilities, our local commercial branch has grown to over 340 employees. Our commercial portfolio in Mexico encompasses about 32 products spanning prescription pharmaceuticals,  over-the-counter (OTC) and infant formula segments. Mexico has rapidly grown into one of Eurofarma's largest international subsidiaries outside Brazil, delivering annual growth rates between 10% and 15%.

Q: How does the Mexican pharmaceutical market compare to other regional markets like Chile or Brazil?

A: While specific market dynamics vary, the fundamental pharmaceutical landscapes across Latin America share core similarities. Countries like Brazil, Chile, and Mexico face comparable healthcare delivery models, regulatory challenges, and patient access requirements. However, Mexico stands out due to its high demand for specialized care and critical treatment options. Beyond general epidemiological trends, significant opportunities exist in Mexico to enhance healthcare access and address unmet patient needs.

Q: How does Eurofarma align its innovation strategy with the specific healthcare needs of the Mexican market?

A: Innovation extends beyond simply discovering new molecular entities; it encompasses novel pharmaceutical formulations, enhanced delivery mechanisms, and improved commercial strategies. Our strategy focuses on closing accessibility gaps by introducing differentiated formulations, new molecules, value-added therapies, and digital therapy solutions. As a relatively young subsidiary in Mexico, our objective is to continually build out a high-value portfolio that directly addresses local therapeutic shortfalls.

Q: What are the primary growth drivers and regulatory dynamics shaping Eurofarma’s position in Mexico?

A: Our expansion is guided by broad global corporate strategy and objectives, focused on ensuring that Eurofarma maintains a strong presence across the Americas.

Long-term commercial sustainability requires navigating regulatory frameworks, evolving market channels, and local competitive challenges. Regarding regulation, health authorities like COFEPRIS enforce high quality and safety standards. Operating in Mexico requires total compliance with these rigorous parameters to ensure that every therapy introduced maintains safety, efficacy, and quality. For Eurofarma, it is a priority to collaborate and operate in strict compliance with the regulatory requirements of each country in which we operate, and Mexico is no exception. 

Q: Which medications will Eurofarma introduce into the Mexican market in the short term?

A: We are actively pursuing regulatory approval for Cenobamate, an advanced treatment option for drug-resistant epilepsy, which presents severe clinical challenges for patients and families when conventional therapies fail to achieve seizure control.

Having already secured registration and launched commercialization in other regional markets, Eurofarma aims to make Mexico the fourth Latin American country to offer this therapeutic solution (BR, CL and PE already have it), which will represent a significant improvement in the quality of life of those currently living with this type of epilepsy.

Q: How does Eurofarma balance its product portfolio across prescription drugs, generics, hospital treatments, and specialized care?

A: Our portfolio design is market-driven. Whenever we identify an unaddressed therapeutic requirement or a commercial gap where Eurofarma can deliver a reliable solution, we deploy resources to service that segment, regardless of whether it falls under primary care, specialty medicine, or hospital supply.

Q: Which new partnerships is Eurofarma developing in Mexico?

A: In addition to our ongoing entry into women's health, a segment where Eurofarma holds a strong position regionally, we continuously evaluate strategic alliances. For example, Eurofarma Mexico recently finalized a commercial partnership with Nutricia, Danone’s specialized nutrition division, to enter the specialized medical nutrition segment. Partnering with established category leaders allows us to expand into complementary therapeutic sectors efficiently.

Q: How does Eurofarma utilize commercial data and market intelligence to guide its local operational strategy?

A: Market intelligence and data analytics are central to our decision-making. Our corporate headquarters in Brazil provides a mature blueprint for data utilization, which we adapt to local market dynamics. Rather than imposing rigid, standardized templates, we use market data to understand local channel realities, demand patterns, and patient logistics, allowing us to build sustainable organic growth.

Our immediate priority remains organic growth, as we aim to expand therapeutic coverage, strengthen strategic partnerships, and deliver high-quality pharmaceuticals to patients efficiently.

Q: What is your operational outlook for 2026, and what internal benchmarks define success for the subsidiary?

A: The Mexican pharmaceutical sector in 2026 reflects a stabilized market environment following recent macroeconomic and industry shifts. Despite regulatory, climatic, and channel supply disruptions, Eurofarma Mexico maintains a positive growth trajectory. Beyond commercial metrics, our internal success is defined by organizational benchmarks, including workplace culture certifications (such as Great Place to Work), gender equity, and employee development. We operate on the principle that sustainable business performance is driven directly by our workforce.

We want physicians, partners, and patients in Mexico to know that behind every Eurofarma product is an absolute commitment to quality, safety, and clinical efficacy. As a younger player in the Mexican market, we are dedicated to building long-term trust, fostering female executive leadership in the pharmaceutical industry, and establishing Eurofarma as a premier healthcare partner across the country.